Lv4
490 积分 2022-08-22 加入
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48‐ADC) combined immunotherapy in patients with muscle‐invasive bladder cancer: A multi‐center real‐world study
6小时前
待确认
Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
2天前
已完结
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial
2天前
已完结
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
2天前
已完结
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
2天前
已完结
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
6天前
已完结
Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma
16天前
已关闭
Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis
16天前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
24天前
已完结
Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers
24天前
已完结
皖公网安备34019202002308
